ANGPTL4 plays a key role in the pathogenesis of various retinopathies, including diabetic retinopathy, and several studies have suggested that targeting ANGPTL4, in particular cANGPTL4, may be beneficial in combination with VEGF-targeted therapies [72,116,122,157]. Here, VEGFA is linked to retinal disorder.